GLTO
Galecto, Inc.·Healthcare
25.85
3.147%(−0.84)
Market ClosedLast Updated: — ET
52W L: $2.0152W H: $38.33
GLTO NEWS
defenseworld.net
Mar 4
Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and two
defenseworld.net
Mar 2
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
Galecto, Inc. (NASDAQ: GLTO - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 277,004 shares, a growth of 86.6% from the January 29th total of 148,474 shares. Approximately 19.4% of the company's stock are short sold. Based
globenewswire.com
Feb 12
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggregate gross proceeds to Galecto from the offering were approximately $316.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto.
globenewswire.com
Feb 10
Galecto Announces Pricing of $275 Million Underwritten Public Offering
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto and assuming no exercise of the underwriters' option to purchase additional shares.
defenseworld.net
Jan 18
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts
Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one
defenseworld.net
Jan 16
Analysts Set Galecto, Inc. (NASDAQ:GLTO) PT at $41.00
Galecto, Inc. (NASDAQ: GLTO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has assigned a
